A potential role for nilotinib in KIT-mutated melanoma

Expert Opinion on Investigational Drugs

Volumn 21, Issue 6, 2012, Pages 861-869

  Tran, An ^a   Tawbi, Hussein A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Dasatinib; Imatinib; KIT; Metastatic melanoma; Nilotinib; Targeted therapy

Indexed keywords

DACARBAZINE; DASATINIB; ERLOTINIB; FLUORODEOXYGLUCOSE; GEFITINIB; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; SUNITINIB; TEMOZOLOMIDE; VEMURAFENIB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIT GENE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRURITUS; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MELANOMA; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SKIN NEOPLASMS;

EID: 84861043641     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.679341     Document Type: Review

References (49)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010, CA. Cancer J Clin 2010;60(5):277
2. World Health Organization. Skin cancers. Available from: http://www.who. int/uv/faq/skincancer/en/index1.html [Accessed 4 June 2010]
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
4. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25 (Pubitemid 41095046)
5. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45 (Pubitemid 46630937)
6. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-5701
7. Middleton MR, Grab JJ, Aaronson N, et al. Randomized Phase III study of Temozolomide Versus Dacarbazine in the Treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66 (Pubitemid 30036349)
8. Parkinson DR, Abrams JS, Wiernik PH, et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990;8:1650-6 (Pubitemid 20334319)
9. Agarwala S. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way. Am J Clin Dermatol 2003;4:333-46 (Pubitemid 36560719)
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N Engl Med. 2010;363:711-23
11. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
12. Fecher LA, Cummings SD, Keefe MJ, et al. Toward a molecular classification of melanoma. J Clin Oncol 2007;25:1606-20 (Pubitemid 46733089)
13. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic Melanoma. N Engl J Med 2010;363:809-19
14. Ribas A, Kim KB, Schuchter LM. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011;29(Suppl):abstract 8509
15. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
16. Krause DS, Van Etten RA. Mechanisms of disease: tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87 (Pubitemid 41058349)
17. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80 (Pubitemid 28067289)
18. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6 (Pubitemid 46630793)
19. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007;121:257-64 (Pubitemid 46917693)
20. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-22 (Pubitemid 41185118)
21. Willmore-Payne C, Layfield LJ, Holden JA. c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens. Cancer 2005;105:165-70 (Pubitemid 40868896)
22. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF-and c-Kit-activating mutations by high-resolution amplicon melting curve analysis. Hum Pathol 2005;36:486-93 (Pubitemid 40776001)
23. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-51
24. Wyman K, Atkins MB, Prieto V, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005-11 (Pubitemid 43673217)
25. Eton O, Billings L, Kim K, et al. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). J Clin Oncol 2004;22(717s Suppl):abstract 7528
26. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398-405 (Pubitemid 40705006)
27. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a Therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34
28. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification. J Clin Oncol 2011;29:2904-9
29. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34 (Pubitemid 351264344)
30. Woodman SE, Trent JC, Lazar SHA, et al. Selective activity of dasatinib for the most common KIT mutation in melanoma (L576P). J Clin Oncol 2009;27(15s Suppl):abstract 9019
31. Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011;117:2202-8
32. Kalinsky K, Lee SJ, Lawrence DP, et al. A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: an Eastern Cooperative Oncology Group study (E2607). Journal of Clinical Oncology 2010;28(15s Suppl):TPS312
33. Cho JH, Kim KM, Kwon M, et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 2011;Published online: 09 November 2011
34. Sawaki A, Nishida T, Doi T, et al. Phase 2 Study of Nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011;117:4633-41
35. Jarkowski A, Sweeney RP. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Pharmacotherapy 2008;28(11):1374-82
36. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51 (Pubitemid 43882350)
37. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib(formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6 (Pubitemid 350159618)
38. Manley PW, Bruggen J, Fabbro D, et al. Extended kinase profiling of the Bcr-Abl inhibitor nilotinib [abstract]. Proc Am Assoc Cancer Res 2007;48:abstract 3249
39. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (Formerly AMN107), a Highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110(10):3540-6 (Pubitemid 350159618)
40. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362(24):2251-9
41. Prenen H, Guetens G, De Boeck G, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006;77:11-16
42. Tanaka C, Yin OQP, Sethuraman V, et al. Tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010;87:197-203
43. Cullinane C, Natoli A, Hui Y, et al. Imatinib-Resistant KIT-driven tumor model preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model. Mol Cancer Ther 2010;9:1461-8
44. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12(9):841-51
45. Available from: http://www. evaluatepharma.com/Universal/View.aspx? type=Story&id=242067
46. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation. Clin Cancer Res 2005;11(11):4182-90 (Pubitemid 40791584)
47. Sapi Z, Fule T, Hajdu M, et al. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol 2011;20(1):22-33
48. Pantaleo MA, Astolfi A, Nannini M, et al. The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). J Transl Med 2010;8:117
49. Muhlenberg T, Zhang Y, Wagner AJ, et al. Inhibitors of Deacetylases suppress oncogenic KIT gastrointestinal stromal tumors signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 2009;69:6941-50